YMAB vs. AKBA, OCS, LENZ, PRAX, ZYME, CMRX, CDMO, NUVB, QURE, and XERS
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Akebia Therapeutics (AKBA), Oculis (OCS), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Nuvation Bio (NUVB), uniQure (QURE), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.
Y-mAbs Therapeutics vs. Its Competitors
Akebia Therapeutics (NASDAQ:AKBA) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends.
Akebia Therapeutics received 279 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. However, 64.00% of users gave Y-mAbs Therapeutics an outperform vote while only 63.13% of users gave Akebia Therapeutics an outperform vote.
Akebia Therapeutics has a net margin of -27.07% compared to Y-mAbs Therapeutics' net margin of -28.22%. Akebia Therapeutics' return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.
Y-mAbs Therapeutics has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 70.8% of Y-mAbs Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 22.5% of Y-mAbs Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Akebia Therapeutics had 12 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 22 mentions for Akebia Therapeutics and 10 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 1.04 beat Akebia Therapeutics' score of 0.87 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media.
Akebia Therapeutics presently has a consensus target price of $6.75, indicating a potential upside of 84.93%. Y-mAbs Therapeutics has a consensus target price of $15.60, indicating a potential upside of 236.93%. Given Y-mAbs Therapeutics' higher possible upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Akebia Therapeutics.
Akebia Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Summary
Y-mAbs Therapeutics beats Akebia Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:YMAB) was last updated on 6/12/2025 by MarketBeat.com Staff
